Carregant...
Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactori...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535933/ https://ncbi.nlm.nih.gov/pubmed/23147724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01611-12 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|